D. Caballero

发表

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

N. Schmitz, A. Hunter, C. Kyriakou, 2008 .

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting

P. Ljungman, M. Remberger, O. Ringdén, 2018, Medical Oncology.

Evaluation of prognostic factors among patients with chronic graft-versus-host disease

J. Miguel, J. Pérez-Simón, M. Remberger, 2012, Haematologica.

Chronic Graft-Versus-Host Disease

J. S. San Miguel, J. Pérez-Simón, M. Díez-Campelo, 2012, Drugs.

Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft‐versus‐host disease after allogeneic peripheral blood stem cell transplant

E. Colado, F. Sánchez-Guijo, J. S. San Miguel, 2010, American journal of hematology.

Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.

J. S. San Miguel, J. Pérez-Simón, T. Caballero-Velázquez, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.

E. Colado, F. Sánchez-Guijo, J. S. San Miguel, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).

F. Sánchez-Guijo, J. S. San Miguel, E. Ocio, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

A. Ganser, J. Johansson, R. Fanin, 2020, Bone Marrow Transplantation.

Incidence and risk factors for life‐threatening bleeding after allogeneic stem cell transplant

J. González-Porras, F. Sánchez-Guijo, J. Labrador, 2015, British journal of haematology.

Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience

R. Martino, J. Díez-Martín, P. Balsalobre, 2011, Therapeutic advances in hematology.

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

J. Delgado, J. Sierra, C. Solano, 2010, Haematologica.

Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.

J. Briones, J. Queraltó, J. Sierra, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome

N. Schmitz, A. Pettitt, N. Russell, 2009, Haematologica.

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, L. Kanz, N. Russell, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes

J. Garcia-conde, J. Sierra, S. Mackinnon, 2007, British journal of haematology.

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

C. Solano, L. Bento, M. Bastos-Oreiro, 2022, Cancers.

Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

G. Gutiérrez-García, C. Solano, J. Pérez-Simón, 2021, Bone Marrow Transplantation.

Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT

S. Montoto, P. Chevallier, D. Blaise, 2020, Bone Marrow Transplantation.

Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation

C. Solano, R. Martino, S. Querol, 2018, Bone Marrow Transplantation.

Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

J. Miguel, S. Brunet, J. Pérez-Simón, 2003, Blood.

Population pharmacokinetics of amikacin in patients with haematological malignancies.

J. M. Lanao, A. Domínguez-Gil, M. V. Calvo, 1999, The Journal of antimicrobial chemotherapy.

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.

J. S. San Miguel, J. Hernández, A. Domínguez-Gil, 1996, Clinical pharmacology and therapeutics.

Autologous stem cell transplantation for poor prognosis Hodgkin’s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group

J. Garcia-conde, J. Maldonado, S. Brunet, 1997, Bone Marrow Transplantation.

Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

E. González-Barca, S. Mercadal, J. Sancho, 2017, Hematological oncology.

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, A. Hunter, C. Kyriakou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation

H. Putter, N. Kröger, J. Finke, 2017, Bone Marrow Transplantation.

Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

M. Terol, E. Soria-Olivas, C. Solano, 2022, Annals of Hematology.

Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

M. Mateos, C. Cañizo, L. Vázquez, 2004, Bone Marrow Transplantation.

Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

A. Ganser, N. Kröger, M. Robin, 2018, Bone Marrow Transplantation.

Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time

F. Fernández‐Avilés, R. Martino, R. Duarte, 2015, Bone Marrow Transplantation.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

J. Sierra, J. Besalduch, J. Pérez-Simón, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source

S. Brunet, J. Ribera, A. Jiménez-Velasco, 2006, Leukemia.

Chronic but not acute graft‐versus‐host disease improves outcome in multiple myeloma patients after non‐myeloablative allogeneic transplantation

J. S. San Miguel, J. Pérez-Simón, R. Martino, 2003, British journal of haematology.

Graft vs. Host Disease and Graft vs. Myeloma Effect after Non-myeloablative Allogeneic Transplantation

J. S. San Miguel, J. S. San Miguel, J. Pérez-Simón, 2004, Leukemia & lymphoma.

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

J. Miguel, J. Bladé, J. Lahuerta, 2000, British journal of haematology.

Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

J. Finke, D. Blaise, A. Nagler, 2016, Bone Marrow Transplantation.

Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation

E. Montserrat, J. Garcia-conde, C. Solano, 2001, Bone Marrow Transplantation.

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

C. Solano, J. Maldonado, J. S. San Miguel, 2000, The hematology journal : the official journal of the European Haematology Association.

Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.

E. González-Barca, C. Solano, R. Martino, 2021, Transplantation and cellular therapy.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.

J. Sierra, C. Solano, M. Sanz, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.

E. Kimby, N. Schmitz, H. Tilly, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

A. Órfão, J. S. San Miguel, J. Bladé, 2002, Blood.

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

E. Ocio, F. Sánchez-Guijo, J. S. San Miguel, 2005, American journal of hematology.

Haematopoietic damage persists 1 year after autologous peripheral blood stem cell transplantation

J. Miguel, C. Cañizo, L. Vázquez, 1999, Bone Marrow Transplantation.

Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial

V. Diehl, N. Schmitz, R. Marcus, 2004, Bone Marrow Transplantation.

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique

J. Garcia-conde, C. Solano, S. Brunet, 1998, Bone Marrow Transplantation.

Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study

C. Solano, S. Brunet, J. Ribera, 2009, Haematologica.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation

J. Perkins, C. Solano, J. Pidala, 2017, Bone Marrow Transplantation.

Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.

E. Andreu, F. Prósper, F. Sánchez-Guijo, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.

C. Solano, M. Sanz, S. Brunet, 2003, Experimental hematology.

Dry eye disease in chronic graft-versus-host disease: results from a Spanish retrospective cohort study.

T. Barrientos-Gutiérrez, P. de la Parra-Colin, M. Calonge, 2011, Transplantation proceedings.

Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning

R. Martino, J. Bargay, M. González, 2003, Bone Marrow Transplantation.

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

R. López-Pérez, M. González, G. Mateos, 2002, Leukemia.

Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.

J. Sierra, S. Brunet, J. Pérez-Simón, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry

C. Solano, S. Brunet, F. Hernández-Navarro, 1998, Bone Marrow Transplantation.

Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model.

I. Fernández, M. Stern, M. Calonge, 2016, Investigative ophthalmology & visual science.

Effect of vitamin D treatment in chronic GVHD

F. Sánchez-Guijo, J. Pérez-Simón, J. Miguel, 2011, Bone Marrow Transplantation.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

J. Garcia-conde, C. Craddock, S. Mackinnon, 2002, Blood.

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

J. González-Porras, F. Sánchez-Guijo, J. Pérez-Simón, 2014, Bone Marrow Transplantation.

Disparity for the minor histocompatibility antigen HA‐1 is associated with an increased risk of acute graft‐versus‐host disease (GvHD) but it does not affect chronic GvHD incidence, disease‐free survival or overall survival after allogeneic human leucocyte antigen‐identical sibling donor transplanta

A. Grañena, J. Sierra, C. Solano, 2001, British journal of haematology.

Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.

E. Ocio, J. S. San Miguel, J. Pérez-Simón, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings.

E. Montserrat, J. Garcia-conde, C. Solano, 2001, Blood.

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study

C. Solano, F. Sánchez-Guijo, J. Pérez-Simón, 2016, Bone Marrow Transplantation.

The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate

C. Solano, J. Pérez-Simón, R. Martino, 2013, Haematologica.

Neurological Complications after Autologous Stem Cell Transplantation

N. Gutiérrez, J. S. San Miguel, Á. Guerrero, 1999, European Neurology.

Cost‐effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies

J. Hernández, J. S. San Miguel, A. Domínguez-Gil, 1996 .

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients

F. Fernández‐Avilés, J. S. San Miguel, S. Brunet, 2006, Leukemia.

Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

F. Sánchez-Guijo, S. Muntión, J. S. San Miguel, 2012 .

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

Marcos González, J. Miguel, A. Órfão, 1997 .

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.

A. Órfão, J. S. San Miguel, M. González, 1997, Blood.

Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.

J. S. San Miguel, L. Vázquez, D. Caballero, 2005, Haematologica.

Mucormycosis with pulmonary, renal, pancreatic and spleen involvement detected by 18F-FDG PET/CT in a patient who underwent allogeneic stem cell transplantation. Report of case

P. Tamayo, L. Lopez-Corral, D. Caballero, 2019, Trends in Transplantation.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

J. Sierra, M. Perales, S. Devlin, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD34+ selection vs. reduced-intensity conditioning and unmodified graft for allogeneic hematopoietic cell transplantation in patients with AML and MDS > 50 years

J. Sierra, M. Perales, S. Devlin, 2018 .

Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post‐allogeneic transplantation for high‐risk myeloma patients

J. S. San Miguel, J. Pérez-Simón, R. Martino, 2013, British journal of haematology.

Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy.

J. Garcia-conde, C. Solano, C. Richard, 1992, Bone marrow transplantation.

Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

J. Sanz, L. Bento, A. Jiménez-Ubieto, 2020, Bone Marrow Transplantation.

Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation

A. Órfão, J. Pérez-Simón, M. González, 1999, Bone Marrow Transplantation.

M. Labopin, M. Mohty, E. Deconinck, 2010 .

Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings.

E. Montserrat, J. Garcia-conde, C. Solano, 2002, Blood.

To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors

J. Pérez-Simón, C. Calderón, L. Lopez-Corral, 2013, European journal of haematology.

Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma

M. Mateos, C. del Cañizo, L. Lopez-Corral, 2015, Clinical case reports.

siblings selected blood cells from HLA-identical + transplantation with CD34 Risk factors for acute graft-versus-host disease in patients undergoing

C. Solano, J. Bargay, C. Rozman, 2011 .

Favourable effect of the combination of acute and chronic graft‐versus‐host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

J. Sierra, C. Solano, J. Maldonado, 2001, British journal of haematology.

GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT

C. Solano, J. Pérez-Simón, R. Martino, 2015, Bone Marrow Transplantation.

Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: A report from the Spanish GEL/TAMO Cooperative Group

E. Montserrat, J. Garcia-conde, C. Solano, 1993, Annals of Hematology.

Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia

J. S. San Miguel, M. González, C. Cañizo, 2000, British journal of haematology.

Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.

J. S. San Miguel, P. García-Cosmes, L. Vázquez, 2013, European journal of haematology.

Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH)

A. Verdeguer, S. Brunet, J. Díez, 2005, Bone Marrow Transplantation.

peripheral blood from HLA-identical siblings failure after allogeneic transplantation of CD34+ selected cells from The number of donor CD3+ cells is the most important factor for graft

E. Montserrat, J. Sierra, C. Solano, 2013 .

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Joan, M. Rozman, J. Miguel, 1998, The American journal of pathology.

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.

N. Schmitz, A. Ganser, R. Brand, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

L. Bento, M. Bastos-Oreiro, M. Cabrero, 2022, Cancers.

The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

E. Kimby, M. Ghielmini, P. Dreger, 2014, Leukemia.

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)

P. Abrisqueta, N. Villamor, M. Terol, 2016, Bone Marrow Transplantation.

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

J. Delgado, J. Sierra, R. Benjamin, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

M. Terol, C. Solano, P. Armand, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.

N. Schmitz, A. Ganser, R. Brand, 2007 .

Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.

J. S. San Miguel, J. Pérez-Simón, R. Martino, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

C. Solano, M. Sanz, J. Sanz, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients

A. Verdeguer, S. Brunet, J. Díez, 2004, Bone Marrow Transplantation.

Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy

J. Pérez-Simón, C. Cañizo, J. F. Miguel, 2006, Bone Marrow Transplantation.

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.

J. Briones, J. Sanz, L. Bento, 2023, Bone Marrow Transplantation.

The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.

J. Delgado, J. Miguel, J. Sierra, 2007 .

Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment

H. Deeg, A. Bacigalupo, F. Gualandi, 2016 .

Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis

J. Miguel, C. Cañizo, L. Vázquez, 2000, Bone Marrow Transplantation.